eotaxin-1

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomab's CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— —CM-101 Phase 2 PSC Trial Has Completed Patient Enrollment with Topline Data Readout Targeted for Midyear 2024— TEL AVIV, Israel, Jan. 30, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The study, "The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data" 1 has been published in the current online version of the peer-reviewed journal Cells. "The patient sample and other proteomic analyses reported in this publication add to the large and growing body of data showing that CCL24 is a major driver of PSC pathology, providing more detail about its central role in orchestrating the fibrosis and inflammation underlying PSC progression," said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. "These new data further validating our CCL24 target and the clinical rationale for our CCL24-neutralizing antibody are especially timely as we look forward to our CM-101 Phase 2 topline readout expected midyear, which has the potential to deliver the first significant clinical proof-of-concept of CM-101's therapeutic activity in PSC, a lethal disease with no FDA approved therapies." The studies included advanced proteomic analyses of serum samples from PSC patients and healthy controls to further investigate the involvement of CCL24 in PSC and its association with specific disease-related pathways. They confirmed the exclusive association of CCL24 with fundamental PSC mechanisms, with no similar association seen with two other related proteins (CCL11 and CCL26) sharing the same receptor, emphasizing CCL24's unique potential as a target for PSC therapies. Additional studies showed that CCL24 directly contributes to the development of fibrosis and inflammation in PSC via recruitment of monocytes and neutrophils and activation of hepatic stellate cells (HSCs), a major source of the myofibroblasts that are a key driver of liver fibrogenesis. Notably, an invitro analysis pinpointed a CCL24-dependant proteomic signature in HSCs treated with CCL24 that is capable of stratifying PSC patients based on disease severity, offering promise for future disease activity monitoring. CM-101 is a first-in-class CCL24-neutralizing monoclonal antibody whose dual anti-inflammatory and anti-fibrotic activity has demonstrated disease modifying potential in nonclinical studies of PSC and other fibro-inflammatory disorders. CM-101 has Orphan Drug designation for PSC in the U.S. and the European Union and was recently awarded Fast Track designation by the FDA for the treatment of PSC in adults. About Primary Sclerosing Cholangitis PSC is a rare, progressive liver disease characterized by inflammation and fibrosis (scarring) of the bile ducts that can lead to cirrhosis of the liver, liver failure and death. PSC also increases the risk of various cancers, which account for about half of PSC-related mortality. PSC affects an estimated 30,000 patients in the U.S. and about 80,000 worldwide. The underlying cause of PSC is unknown, but about 75% of patients also have inflammatory bowel disease. Currently there are no approved therapies for PSC. Liver transplantation is common in advanced cases, but even then, PSC re-occurs in about 20% of transplanted patients. There is a high unmet need for therapeutic options to address the symptoms and modify the progression of this devastating illness. 1 Greenman, R.; Snir, T.; Katav, A.; Aricha, R.; Mishalian, I.; Hay, O.; Frankel, M.; Lawler, J.; Saffioti, F.; Pinzani, M.; et al. The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data. Cells 2024, 13, 209. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the expectation that Chemomab will report topline data from the PSC clinical trial by mid-year 2024; the length, duration and impact of the war in Israel on Chemomab's business and operations; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including those found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. The CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. For more information about Chemomab, visit chemomab.com. Contacts: Media and Investors: Barbara Lindheim Consulting Vice President, Investor & Public Relations, Strategic Communications Phone: +1 917-355-9234 [email protected] IR@chemomab.com SOURCE Chemomab Therapeutics, Ltd.

DUBLIN, Dec. 7, 2023 /PRNewswire/ -- The "Bertilimumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about bertilimumab for bullous pemphigoid in the seven major markets. A detailed picture of the bertilimumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the bertilimumab for bullous pemphigoid. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the bertilimumab market forecast analysis for bullous pemphigoid in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bullous pemphigoid. Drug Summary Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function. Eotaxin-1 is a potent activator and chemoattractant of eosinophils (disease-fighting human white blood cells). Increased numbers of eosinophils are a feature of several diseases, including those of allergic origin (for example, asthma, rhinitis, inflammatory bowel diseases, and more severe conjunctivitis), and in many cases are believed to be the major cells affecting tissue damage. Eosinophil degranulation products have been shown to have significant toxic effects on tissues, and cytokines are known to be released by eosinophils to enhance the inflammatory cascade. Eotaxin-1 has a substantial role in the process by which eosinophils are recruited into tissues. It is also involved in eosinophil activation. By blocking eotaxin-1, one may be able to prevent or reduce tissue eosinophil accumulation and, as a result, prevent subsequent tissue injury. Recently, bertilimumab has been investigated in a Phase II trial to treat newly diagnosed moderate-to-extensive BP. The trial targeted patients with BP and revealed good safety and efficacy results. Bertilimumab Analytical Perspective In-depth Bertilimumab Market Assessment This report provides a detailed market assessment of bertilimumab for bullous pemphigoid in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032. Bertilimumab Clinical Assessment The report provides the clinical trials information of bertilimumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates. Report Highlights In the coming years, the market scenario for bullous pemphigoid is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence bertilimumab dominance. Other emerging products for bullous pemphigoid are expected to give tough market competition to bertilimumab and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of bertilimumab in bullous pemphigoid. This in-depth analysis of the forecasted sales data of bertilimumab from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the bertilimumab in bullous pemphigoid. Key Topics Covered: 1. Report Introduction 2. Bertilimumab Overview in bullous pemphigoid 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. Bertilimumab Market Assessment 5.1. Market Outlook of Bertilimumab in bullous pemphigoid 5.2. 7MM Analysis 5.2.1. Market Size of Bertilimumab in the 7MM for bullous pemphigoid 5.3. Country-wise Market Analysis 5.3.1. Market Size of Bertilimumab in the United States for bullous pemphigoid 5.3.2. Market Size of Bertilimumab in Germany for bullous pemphigoid 5.3.3. Market Size of Bertilimumab in France for bullous pemphigoid 5.3.4. Market Size of Bertilimumab in Italy for bullous pemphigoid 5.3.5. Market Size of Bertilimumab in Spain for bullous pemphigoid 5.3.6. Market Size of Bertilimumab in the United Kingdom for bullous pemphigoid 5.3.7. Market Size of Bertilimumab in Japan for bullous pemphigoid 6. SWOT Analysis 7. Analysts' Views For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

—New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101— —Oral Presentation of Proteomic Analyses in PSC Patients Provides Further Evidence that CCL24 Is a Key Driver of the Inflammatory and Fibrotic Processes Underlying PSC and Other Disorders— TEL AVIV, Israel, Nov. 13, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported on its oral and poster presentations at AASLD's The Liver Meeting® 2023, being held November 10-14, 2023. In an oral presentation by Ilan Vaknin, PhD, Chemomab's Vice President of R&D, analysis of serum samples from patients with primary sclerosing cholangitis (PSC) provided further evidence that the soluble protein CCL24 is associated with key inflammatory and fibrotic pathways implicated in the liver damage characterizing PSC.1 Chemomab's first-in-class monoclonal antibody CM-101 is designed to neutralize CCL24 and normalize PSC's fibro-inflammatory disease processes. CM-101 is currently in a Phase 2 trial in PSC patients that is advancing towards completion of enrollment. A top-line data readout is expected in the second half of next year. There currently are no FDA-approved therapies for this devastating, often lethal disease. A poster presentation hosted by Matt Frankel, MD, Chief Medical Officer of Chemomab, described key findings from proteomic analyses of serum samples at baseline and after 16 weeks of treatment with CM-101 from the company's Phase 2a liver fibrosis trial in patients with nonalcoholic steatohepatitis (NASH).2 These analyses demonstrated consistent and significant reductions in liver-related pathology pathways that lead to liver damage, activation of liver fibroblasts and liver steatosis. Moreover, proteomic analysis showed that CM-101 treatment led to significant downregulation in multiple immune-related pathways, along with an increase in metabolic pathways associated with improved glucose and fat metabolism. The study also indicated that CM-101 has a strong and specific target engagement profile for CCL24. "These new data using advanced proteomic analytic tools add to the extensive body of evidence that CCL24 is a major driver of fibrotic and inflammatory processes underlying PSC and other fibrotic liver diseases," said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. "These data also confirm that key features of PSC are uniquely associated with high levels of CCL24. We are rapidly advancing towards completion of patient enrollment in our Phase 2 PSC trial and look forward to a top-line data readout in the coming year." The PSC oral presentation describes advanced proteomics analyses of serum samples from PSC patients and healthy controls. The study showed that PSC disease-related pathways, upstream disease regulators and PSC-related toxicity functions are elevated in patients with high CCL24 levels. The analysis also revealed the unique association of CCL24 with PSC mechanisms, with no similar association with two other members of the same subfamily (CCL11 and CCL26) that share the same receptor as CCL24. The authors note that this study provides further evidence of the critical role of CCL24 in the pathogenesis of PSC, highlighting its unique association with disease-related pathways. Copies of Chemomab's oral and poster presentations from AASLD's The Liver Meeting® 2023 are available at 1-Serum proteomics reveals unique association of CCL24 with disease-related pathways and signatures in primary sclerosing cholangitis, T Snir, R Greenman, R Aricha, J Lawler, F Saffioti, D Thorburn, M Pinzani, A Mor, I Vaknin. Session--Breaking the Chains of Cholestatic Liver Injury: Advancements and Promising Treatment Strategies 2- CM-101, a CCL24 neutralizing antibody, showed improvements in inflammatory, fibrotic, and metabolic pathways in patients with NASH: Proteomics analysis of a Phase 2a study, R Aricha, T Snir, I Vaknin, J Lawler, A Mor, M Frankel Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the length, duration and impact of the war in Israel on Chemomab's business and operations; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including those found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from three clinical trials of CM-101 in patients, including a Phase 1b trial in NAFLD patients, a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. The CM-101 program for the treatment of systemic sclerosis is Phase 2-ready and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with topline data expected in the second half of 2024. For more information about Chemomab, visit chemomab.com. Contacts: Media and Investors: Barbara Lindheim Consulting Vice President, Investor & Public Relations, Strategic Communications Phone: +1 917-355-9234 [email protected] [email protected] SOURCE Chemomab Therapeutics, Ltd.